Psyched Wellness Completes Extraction Protocol For First Mushroom Products

Psyched Wellness (CSE: PSYC) has completed a number of milestones with regards to getting its first amanita muscaria mushroom products to market. The company announced this morning that it has completed lab experiments that are comprehensive in nature for the final extraction protocol for the amanita muscaria mushroom.

The protocol for extraction will then be used to enable the company to get the first line of products to market. The material safety data sheet for its amanita muscaria extract has also been completed, along with assembly of safety and efficacy narratives.

The completion of the extraction protocol will essentially allow for the company to expand operations in terms of production, while also enabling a higher yield and capacity of the psychoactive compound found within the Amanita Muscaria mushroom, known as Muscimol.

“With the completion of the final extraction process and finalizing the SDS, we are now able to start producing larger-scale extraction and ship it abroad. The team is doing a great job and I am confident we will be able to start our pre-clinical trials with our CRO partner in Asia before year ends.”

David Shisel, Chief Operating Officer of Psyched Wellness

The announcement of a completed extraction protocol follows the news earlier this week that Psyched has completed its toxicology assessment on the Amanita Muscaria mushroom. The results, which were positive in nature, have enabled the firm to move ahead with establishing a path to market for its products. The company is working towards submitted to the US FDA and Health Canada for classification as a new dietary ingredient and a natural health product, respectively.

Cambria Gold Mines — sponsored Sponsored · Cambria Gold Mines

Psyched Wellness last traded at $0.25 on the CSE.


FULL DISCLOSURE: Psyched Wellness is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Psyched Wellness on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

The Gold & Copper Stocks Everyone Keeps Asking About | Oct. 12-16 – Weekly Mining Mailbag

Similar Gold Mines Are Valued 10X Higher. Why Not This One? | JW Dumont – Granada Gold Mine

The US Interest Bill Gold Can’t Ignore | Peter Grandich

Recommended

Cambria’s Silver Coin Infill Program Delivers 98.56 g/t Gold Over 8.2 Metres

First Majestic Produces 3.4 Million Ounces of Silver in Q3 2026, Jerritt Canyon Restart Remains on Track

Related News

Psyched Wellness Submits Trademark For Amanita Muscaria Extract

Psyched Wellness (CSE: PSYC) is looking to build up its portfolio of intellectual property. The...

Thursday, January 21, 2021, 07:01:48 AM

Psyched Wellness Sees Amanita Muscaria Approved As Medicinal Organism By Health Canada

After more than a years worth of development work, Psyched Wellness (CSE: PSYC) this morning...

Wednesday, November 3, 2021, 08:10:25 AM

Psyched Wellness Sees Professor David Nutt Move From Advisory Role To Directorship

It appears that Professor David Nutt has a desire to become more involved with that...

Monday, November 16, 2020, 08:11:48 AM

Psyched Wellness Moves To Next Stage Of Pre-Clinical Trials With Mushroom Extract

Psyched Wellness (CSE: PSYC) continues to execute on its strategy as it pertains to the...

Thursday, October 7, 2021, 08:21:06 AM

David Nutt: Amanita Muscaria Due For More Research – The Daily Dive

Today on the Daily Dive, our host Cassandra Leah sits down with Dr David Nutt,...

Wednesday, March 10, 2021, 01:30:00 PM